Education
About Us
Working with TipRanks
Follow Us
Larimar Therapeutics, Inc. (LRMR)
NASDAQ:LRMR
LRMR Stock Chart & Stats
$5.31
-$0.11(-2.78%)
At close: 4:00 PM EST
$5.31
-$0.11(-2.78%)
Day’s Range― - ―
52-Week Range$1.61 - $6.42
Previous CloseN/A
Volume147.46K
Average Volume (3M)6.48M
Market Cap
$454.48M
Enterprise Value$361.84M
Total Cash (Recent Filing)$175.44M
Total Debt (Recent Filing)$4.35M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Mar 18, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding85,590,390
10 Day Avg. Volume17,332,603
30 Day Avg. Volume6,477,397
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.38
Price to Sales (P/S)0.00
P/FCF Ratio-3.33
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.07K
Enterprise Value/Ebitda-2.63
Forecast
1Y Price Target
$16.67Price Target Upside213.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.82
Revenue Forecast (FY)$2.32M
Bulls Say, Bears Say
Bulls Say
Clinical Evidence ConfidencePromising functional patient data versus the FACOMS natural history and observed frataxin protein expression increase analyst confidence in the therapy's clinical efficacy for Friedreich's ataxia.
Regulatory DesignationFDA Breakthrough Therapy designation for the lead therapy meaningfully derisks the regulatory pathway and supports more focused interactions with regulators during review.
Regulatory Incentives And Valuation UpsideBreakthrough status could enable eligibility for a priority review voucher and underpins analyst views that the stock is undervalued with upside tied to acceptance of the regulatory filing.
Bears Say
External Comparator Alignment RiskFurther alignment with regulators on how trial results will be compared to the external FACOMS database remains necessary and creates uncertainty around approval comparisons.
Regulatory Timing And Filing RiskUnresolved issues over trial comparisons and endpoints could lead to delays in filing acceptance or extend the overall review timeline, affecting near-term approval prospects.
Surrogate Endpoint Acceptance RiskRegulatory acceptance of skin frataxin levels as a surrogate marker for symptoms is not guaranteed and may require additional evidence or design changes to satisfy reviewers.
Larimar Therapeutics News
LRMR FAQ
What was Larimar Therapeutics, Inc.’s price range in the past 12 months?
Larimar Therapeutics, Inc. lowest stock price was $1.61 and its highest was $6.42 in the past 12 months.
What is Larimar Therapeutics, Inc.’s market cap?
Larimar Therapeutics, Inc.’s market cap is $454.48M.
When is Larimar Therapeutics, Inc.’s upcoming earnings report date?
Larimar Therapeutics, Inc.’s upcoming earnings report date is Mar 18, 2026 which is in 15 days.
How were Larimar Therapeutics, Inc.’s earnings last quarter?
Larimar Therapeutics, Inc. released its earnings results on Nov 05, 2025. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.404 by -$0.206.
Is Larimar Therapeutics, Inc. overvalued?
According to Wall Street analysts Larimar Therapeutics, Inc.’s price is currently Undervalued.
Does Larimar Therapeutics, Inc. pay dividends?
Larimar Therapeutics, Inc. does not currently pay dividends.
What is Larimar Therapeutics, Inc.’s EPS estimate?
Larimar Therapeutics, Inc.’s EPS estimate is -0.49.
How many shares outstanding does Larimar Therapeutics, Inc. have?
Larimar Therapeutics, Inc. has 85,590,390 shares outstanding.
What happened to Larimar Therapeutics, Inc.’s price movement after its last earnings report?
Larimar Therapeutics, Inc. reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.404. Following the earnings report the stock price went down -15.263%.
Which hedge fund is a major shareholder of Larimar Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LRMR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Larimar Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.67 (213.94% Upside)
$16.67 (213.94% Upside)
Blogger Sentiment
Bullish
LRMR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 6.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $550.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.6%
Last 30 Days ▼ 9.6%
Last 30 Days ▼ 9.6%
News Sentiment
Very Bullish
Bullish news 91%
Bearish news 9%
Bearish news 9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
81.84%
12-Months-Change
Fundamentals
Return on Equity
-78.24%
Trailing 12-Months
Asset Growth
-14.46%
Trailing 12-Months
Company Description
Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
LRMR Stock 12 Month Forecast
Average Price Target
$16.67
▲(213.94% Upside)
Technical Analysis
Omeros
―
Vanda
―
Foghorn Therapeutics
―
Candel Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
Currently, No data available
---